SCIENTIFIC REPORT 2004 - Sylvester Comprehensive Cancer Center

More documents

Recommendations

Info

P U B L I C A T I O N S 2 0 0 2 - 2 0 0 3 Strbo, N, Oizumi, S, Sotosek-Tokmadzic, V, and Podack, ER. Perforin is required for innate and adaptive immunity induced by heat shock protein gp96. Immunity 18:381-90, 2003. Gulan, G, Ravlic-Gulan, J, Strbo, N, Sotosek, V, Nemec, B, Matovinovic, D, Rubinic, D, Podack, ER, and Rukavina, D. Systemic and local expression of perforin in lymphocyte subsets in acute and chronic rheumatoid arthritis. Journal of Rheumatology 30:660-70, 2003. Dix, RD, Podack, ER, and Cousins, SW. Murine cytomegalovirus retinitis during retrovirus-induced immunodeficiency (MAIDS) in mice: interleukin-2 immunotherapy correlates with increased intraocular levels of perforin mRNA. Antiviral Research 59:111-19, 2003. Raez, L, Cassileth, PA, Schlesselman, JJ, Padmanabhan, S, Fisher, EZ, Baldie, PA, Sridhar, K, and Podack, ER. Induction of CD8 T cell-Ifng response and positive clinical outcome after immunization with gene modified allogeneic tumor cells in advanced non-small cell lung carcinoma. Cancer Gene Therapy 10:850-58, 2003. Santos, ES, Raez, LE, Salvatierra, J, Morgensztern, D, Shanmugan, N, and Neff, GW. Primary hepatic non-Hodgkin’s lymphomas: a case report and review of the literature. American Journal of Gastroenterology (Review) 98:2789- 93, 2003. Raez, LE, Cassileth, PA, Schlesselman, JJ, Padmanabhan, S, Fisher, EZ, Baldie, PA, Sridhar, K, and Podack, ER. Induction of CD8 T-cell-Ifngamma response and positive clinical outcome after immunization with gene modified allogeneic tumor cells in advanced non-small cell lung carcinoma. Cancer Gene Therapy 10:850-58, 2003. Santos, ES, Raez, LE, Kharfan-Dabaja, MA, Angulo, J, Restrepo, A, and Byrnes, JJ. Survival of renal allograft following de novo hemolytic uremic syndrome after kidney transplantation. Transplantation Proceedings 35:1370-74, 2003. Riley, RL, Knowles, J, and King, AM. Levels of E2A protein expression in B cell precursors are stage-dependent and inhibited by stem cell factor (c-kit ligand). Experimental Hematology 30:1412-18, 2002. Van Der Put, E, Sherwood, EM, Blomberg, BB, and Riley, RL. Aged mice exhibit distinct B cell precursor phenotypes differing in activation, proliferation, and apoptosis. Experimental Gerontology 38:1137-47, 2003. Frasca, D, Nguyen, D, Riley, RL, and Blomberg, BB. Decreased E12 and/or E47 transcription factor activity in the bone marrow as well as in the spleen of aged mice. Journal of Immunology 170:719-26, 2003. Sherwood, EM, Xu, W, and Riley, RL. B cell precursors in senescent mice exhibit decreased recruitment into proliferative compartments and altered expression of Bcl-2 family members. Mechanisms of Ageing and Development 124:147-53, 2003. Frasca, D, Nguyen, D, Riley, RL, and Blomberg, BB. Effects of aging on proliferation and E47 transcription factor activity induced by different stimuli in murine splenic B cells. Mechanisms of Ageing and Development 124:361-69, 2003. Frasca, D, Nguyen, D, Van Der Put, E, Riley, RL, and Blomberg, BB. The age-related decrease in E47 DNA-binding does not depend on increased Id inhibitory proteins in bone marrowderived B cell precursors. Frontiers in Bioscience 8:A110-6, 2003. Frasca, D, Nguyen, D, Riley, RL, and Blomberg, BB. Decreased E12 and/or E47 transcription factor activity in the bone marrow as well as in the spleen of aged mice. Journal of Immunology 170:719-26, 2003. UM/Sylvester Comprehensive Cancer Center Scientific Report 2004 179
P U B L I C A T I O N S 2 0 0 2 - 2 0 0 3 Wilson, EL, Sherwood, EM, King, AM, and Riley, RL. A phenotypically distinct subset of bone marrow immature B cells exhibits partial activation, increased survival, and preferential expression of VhS107. European Journal of Immunology 33:3398, 2003. Rocha Lima, CM, Herndon, JE 2nd, Kosty, M, Clamon, G, and Green, MR. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 94:181-87, 2002. Rocha Lima, CM, Savarese, D, Bruckner, H, Dudek, A, Eckardt, J, Hainsworth, J, Yunus, F, Lester, E, Miller, W, Saville, W, Elfring, GL, Locker, PK, Compton, LD, Miller, LL, and Green, MR. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. Journal of Clinical Oncology 20:1182-91, 2002. Rocha Lima, CM, Leong, SS, Sherman, CA, Perkel, JA, Putman, T, Safa, AR, and Green, MR. Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Huntington) 16:19-24, 2002. Rocha Lima, CM and Centeno, B. Update on pancreatic cancer. Current Opinion in Oncology 14:424-30, 2002. Rocha Lima, CM and Joppert, MG. Topoisomerase I-based nonplatinum combinations in non-small cell lung cancer. Oncology (Huntington) 16:25-31, 2002. Freitas, JR and Rocha Lima, CM. Therapy of advanced non-small cell lung cancer with irinotecan and gemcitabine incombination. Clinical Lung Cancer 4: Supplement 1(S26-90), 2002. Coutinho, AK and Rocha Lima, CM. Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control 10:224-38, 2003. Rocha Lima, CM and Chiappori, A. Treatment of relapsed small-cell lung cancer—a focus on the evolving role of topotecan. Lung Cancer 40:229- 36, 2003. Bhargava, P, Jani, CR, O’Donnel, JL, Stuart, KE, and Rocha Lima, CM. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer. Oncology 17: 23-26, 2003. Chiappori, AA, and Rocha Lima, CM. New agents in the treatment of small-cell lung cancer: focus on gemcitabine. Clinical Lung Cancer 4 (Supplement 2): S56-63, 2003. Simon, GR, Ruckdeschel, JC, Williams, C, Cantor, A, Chiappori, A, Rocha Lima, CM, Antonia, S, Haura, E, Wagner, H, Robinson, L, Sommers, E, Alberts, M, and Bepler, G. Gefitinib (ZD1839) in previously treated advanced nonsmall cell lung cancer: experience from a single institution. Cancer Control 10:388-95, 2003. Yang, ES, Maiorino, CA, Roos, BA, Knight, SR, and Burnstein, KL. Vitamin-D mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Molecular and Cellular Endocrinology 186:69–79, 2002. D’Ippolito, G, Schiller, PC, Balkan, W, Roos, BA, and Howard, GA. Cooperative anabolic actions of HGF and 1,25-dihydroxyvitamin D 3 in osteoblastic differentiation of human vertebral marrow stromal fibroblasts. Bone 31:269–75, 2002. Perez-Stable, CM, Schwartz, GG, Farinas, A, Finegold, M, Binderup, L, Howard, GA, and Roos, BA. The Gγ/T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analog EB 1089. Cancer Epidemiology, Biomarkers and Prevention 11:555–63, 2002 Signorile, JF, Carmel, MP, Czaja, SJ, Asfour, SS, Morgan, RO, Khalil, TM, Ma, F, and Roos, BA. Differential increases in average isokinetic power by specific muscle groups of older women due to variations in training and testing. Journal of Gerontology: Medical Sciences 57:M683–M690, 2002. 180 UM/Sylvester Comprehensive Cancer Center Scientific Report 2004
Page 1 and 2:
S C I E N T I F I C R E P O R T 2 0
Page 3 and 4:
I N T R O D U C T I O N A N D P R O
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
L E A D E R S H I P MULTIDISCIPLINA
Page 13 and 14:
L E A D E R S H I P EXTERNAL ADVISO
Page 15 and 16:
C A N C E R P R E V E N T I O N A N
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
C L I N I C A L O N C O L O G Y R E
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
T U M O R C E L L B I O L O G Y P R
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
T U M O R I M M U N O L O G Y P R O
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142: T U M O R I M M U N O L O G Y P R O
Page 143 and 144: V I R A L O N C O L O G Y P R O G R
Page 157 and 158: S H A R E D R E S O U R C E S 3) La
Page 159 and 160: S H A R E D R E S O U R C E S C E L
Page 161 and 162: S H A R E D R E S O U R C E S D N A
Page 163 and 164: S H A R E D R E S O U R C E S G E N
Page 165 and 166: S H A R E D R E S O U R C E S I N F
Page 167 and 168: S H A R E D R E S O U R C E S P O P
Page 169 and 170: P U B L I C A T I O N S 2 0 0 2 - 2
Page 191: P U B L I C A T I O N S 2 0 0 2 - 2
Page 205 and 206: G L O S S A R Y IFN—interferon IL
show all

SCIENTIFIC REPORT 2004 - Sylvester Comprehensive Cancer Center

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?